CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...